Boundary-obstructed topological high-Tc_c superconductivity in iron pnictides

Non-trivial topology and unconventional pairing are two central guiding principles in the contemporary search for and analysis of superconducting materials and heterostructure compounds. Previously, a topological superconductor has been predominantly conceived to result from a topologically non-trivial band subject to intrinsic or external superconducting proximity effect. Here, we propose a new class of topological superconductors which are uniquely induced by unconventional pairing. They exhibit a boundary-obstructed higher-order topological character and, depending on their dimensionality, feature unprecedently robust Majorana bound states or hinge modes protected by chiral symmetry. We predict the 112-family of iron pnictides, such as Ca$_{1-x}$La$_x$FeAs$_2$, to be a highly suited material candidate for our proposal, which can be tested by edge spectroscopy. Because of the boundary-obstruction, the topologically non-trivial feature of the 112 pnictides does not reveal itself for a bulk-only torus band analysis without boundaries, and as such had evaded previous investigations. Our proposal not only opens a new arena for highly stable Majorana modes in high-temperature superconductors, but also provides the smoking gun evidence for extended s-wave order in the iron pnictides.Comment: 8 pages, 4 figures + supplementary material

Fast pyrolysis kinetics of waste tires and its products studied by a wireless-powered thermo-balance

Funding Information: Authors appreciate the financial support from the Liao Ning Revitalization Talents Program (grant number: XLYC2007179 ). Publisher Copyright: © 2023 The AuthorsPeer reviewedPublisher PD

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial

Importance: There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19. Objective: To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. Design, setting, and participants: CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19, was conducted at 21 US hospitals from April 17, 2020, to March 15, 2021. The trial enrolled 941 participants who were hospitalized for 3 or less days or presented 7 or less days after symptom onset and required noninvasive oxygen supplementation. Interventions: A unit of approximately 250 mL of CCP or equivalent volume of placebo (normal saline). Main outcomes and measures: The primary outcome was participant scores on the 11-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement on day 14 after randomization; the secondary outcome was WHO scores determined on day 28. Subgroups were analyzed with respect to age, baseline WHO score, concomitant medications, symptom duration, CCP SARS-CoV-2 titer, baseline SARS-CoV-2 serostatus, and enrollment quarter. Outcomes were analyzed using a bayesian proportional cumulative odds model. Efficacy of CCP was defined as a cumulative adjusted odds ratio (cOR) less than 1 and a clinically meaningful effect as cOR less than 0.8. Results: Of 941 participants randomized (473 to placebo and 468 to CCP), 556 were men (59.1%); median age was 63 years (IQR, 52-73); 373 (39.6%) were Hispanic and 132 (14.0%) were non-Hispanic Black. The cOR for the primary outcome adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval [CrI], 0.75-1.18) with posterior probability (P[cOR Conclusions and relevance: In this trial, CCP did not meet the prespecified primary and secondary outcomes for CCP efficacy. However, high-titer CCP may have benefited participants early in the pandemic when remdesivir and corticosteroids were not in use. Trial registration: ClinicalTrials.gov Identifier: NCT04364737